Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 in Patients of 60 years old or more With adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502585-25-00

Acronym

RC22_0372

Enrollment

Registered

2023-02-07

Start date

2025-02-06

Completion date

Unknown

Last updated

2025-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult patients with adverse Risk Acute Myeloblastic Leukemia

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026